The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with ... Read ...

Researchers from Liverpool School of Tropical Medicine (LSTM) have completed a Phase I clinical trial for a new oral ...

The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted ...

Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...

Annual ResultsBIOVERSYS ANNOUNCES REPORTING DATE FOR FULL-YEAR 2024 FINANCIAL RESULTS AND EVENT DETAILS 14.03.2025 / 07:00 CET/CESTBasel, Switzerland. March 14, 2025, 7am CETBioVersys AG (SIX: BIOV), ...

Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed ...

Presented promising PK, pharmacodynamic, and safety results for Decoy20 at the American Society for Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC) annual meetings.

For a long time, thermal ablation was considered an alternative to surgical resection for patients with malignant liver tumours. However, it should now be regarded as the preferred treatment for ...

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...